HC Wainwright restated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a report released on Monday,Benzinga reports.
Separately, Weiss Ratings downgraded Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.20.
Check Out Our Latest Stock Report on Gossamer Bio
Gossamer Bio Price Performance
Gossamer Bio (NASDAQ:GOSS – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.95 million for the quarter, compared to analysts’ expectations of $4.67 million. On average, equities research analysts anticipate that Gossamer Bio will post -0.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Gossamer Bio by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after purchasing an additional 598,981 shares during the last quarter. Kalehua Capital Management LLC purchased a new position in shares of Gossamer Bio during the 1st quarter worth $3,363,000. State Street Corp increased its position in shares of Gossamer Bio by 139.7% during the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after purchasing an additional 5,427,302 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gossamer Bio by 3.9% during the 4th quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after purchasing an additional 183,183 shares during the last quarter. Finally, Corient Private Wealth LLC raised its holdings in Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after buying an additional 3,825,879 shares during the period. 81.23% of the stock is currently owned by hedge funds and other institutional investors.
About Gossamer Bio
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.
The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.
Featured Articles
- Five stocks we like better than Gossamer Bio
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
